MCH ADVISORY RESEARCH
Health Care

Biotechnology

7 companies under coverage.

Coverage

Biotechnology


Equity Research

Incyte Corporation (INCY)

The bull case — 'Bull — Blockbuster / Pipeline Re-Rate' (8% weight) — targets $193, +70% vs spot. It needs the multiple to hold or expand.

INCYEquity ResearchMonte Carlo
1 July 2026Rating: HOLD · +3%
Equity Research

Regeneron Pharmaceuticals Inc (REGN)

The bull case — 'Bull — Blockbuster / Pipeline Re-Rate' (8% weight) — targets $1,106, +77% vs spot. It needs the multiple to hold or expand.

REGNEquity ResearchMonte Carlo
1 July 2026Rating: HOLD · +1%
Equity Research

Gilead Sciences Inc (GILD)

The bull case — 'Bull — Blockbuster / Pipeline Re-Rate' (8% weight) — targets $216, +71% vs spot. It needs the multiple to hold or expand.

GILDEquity ResearchMonte Carlo
1 July 2026Rating: HOLD · -8%
Equity Research

Biogen Inc (BIIB)

The bull case — 'Bull — Blockbuster / Pipeline Re-Rate' (8% weight) — targets $346, +60% vs spot. It needs the multiple to hold or expand.

BIIBEquity ResearchMonte Carlo
1 July 2026Rating: HOLD · -14%
Equity Research

Amgen Inc (AMGN)

The bull case — 'Bull — Blockbuster / Pipeline Re-Rate' (8% weight) — targets $630, +74% vs spot. It needs the multiple to hold or expand.

AMGNEquity ResearchMonte Carlo
1 July 2026Rating: HOLD · -14%
Equity Research

Vertex Pharmaceuticals Inc (VRTX)

The bull case — 'Bull — Blockbuster / Pipeline Re-Rate' (8% weight) — targets $841, +69% vs spot. It needs the multiple to hold or expand.

VRTXEquity ResearchMonte Carlo
1 July 2026Rating: HOLD · -15%
Equity Research

AbbVie Inc (ABBV)

The bull case — 'Bull — Blockbuster / Pipeline Re-Rate' (8% weight) — targets $418, +66% vs spot. It needs the multiple to hold or expand.

ABBVEquity ResearchMonte Carlo
1 July 2026Rating: HOLD · -15%
MCH ADVISORY SERVICES · All research · Not investment advicemchadvisoryservices.com ↗ · Research Standard v3.2 · US-listed comparatives · UK English